Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants.
Erkens RGA, Calis JJA, Verwoerd A, De Roock S, Ter Haar NM, Den Engelsman G, Van der Veken LT, Ernst RF, Van Deutekom HWM, Pickering A, Scholman RC, Jansen MHA, Swart JF, Sinha R, Roth J, Schulert GS, Grom AA, Van Loosdregt J, Vastert SJ. Erkens RGA, et al. Arthritis Rheumatol. 2024 Jan;76(1):119-129. doi: 10.1002/art.42656. Epub 2023 Nov 6. Arthritis Rheumatol. 2024. PMID: 37471469
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction.
Eloseily E, Pickering A, Dhakal S, Ruperto N, Brunner HI, Grom AA, Thornton S; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Eloseily E, et al. Arthritis Care Res (Hoboken). 2024 Nov 3. doi: 10.1002/acr.25459. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39489688